Medicine guide

Buprenorphine

10 ug/h · Patch

Prescription only
Controlled substance · CIII
Partial Opioid Agonist

Active substance: Buprenorphine
Used in: Pain, sleep, mood, epilepsy and the brain
Made by: Rhodes Pharmaceuticals LLC
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-05-29

What it is

Partial Opioid Agonist

Used for

Buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including…

The label’s usual adult dose

(2.1, 5.1 ) For patients who are not opioid tolerant, initiate treatment with a 5 mcg/hour patch.

Taper the patient's current around-the-clock opioids for up to 7 days to no more than 30 mg of morphine or equivalent per day before beginning treatment with buprenorphine transdermal system.

Full directions ↓

Serious warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUPRENORPHINE TRANSDERMAL SYSTEM Addiction, Abuse, and Misuse Because the use of buprenorphine transdermal system exposes patients and other users to the risks of opioid addiction, abuse, and misuse,…

All warnings ↓

Good to know

Prescription only
Controlled substance (schedule III) — extra rules apply to prescribing and refills
FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02

66other products contain Buprenorphine — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including buprenorphine transdermal system, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic.
Buprenorphine transdermal system is a partial opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including buprenorphine transdermal system for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
( 1 , 5.1 ) Buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic.
( 1 )

From the official label · 2026-05-29 · DailyMed

How it works

From this product’s own US prescribing label.

Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa- opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors.
The contributions of these actions to its analgesic profile are unclear.

Half-life26 h

Mostly cleared after≈ 5 daysfive half-lives — our arithmetic

How the body breaks it down

Since metabolism and excretion of buprenorphine occur mainly via hepatic elimination, reductions in hepatic blood flow induced by some general anesthetics (e.g., halothane) and other drugs may result in a decreased rate of hepatic elimination of the drug, leading to increased plasma concentrations.

How it leaves the body

Following IV administration, buprenorphine and its metabolites are secreted into bile and excreted in urine.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-29

Serious warning

The strongest warning the FDA requires. It is printed in a box at the top of the label.

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUPRENORPHINE TRANSDERMAL SYSTEM Addiction, Abuse, and Misuse Because the use of buprenorphine transdermal system exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] .
Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of buprenorphine transdermal system, especially during initiation or following a dosage increase.
To reduce the risk of respiratory depression, proper dosing and titration of buprenorphine transdermal system are essential.
Misuse or abuse of buprenorphine transdermal system by chewing, swallowing, snorting, or injecting buprenorphine extracted from the transdermal system will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death [see Warnings and Precautions (5.2) ] .
Accidental Exposure Accidental exposure of even one dose of buprenorphine transdermal system, especially in children, can result in a fatal overdose of buprenorphine [see Warnings and Precautions (5.2) ] .
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Reserve concomitant prescribing of buprenorphine transdermal system and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3) , Drug Interactions (7) ] .
Neonatal Opioid Withdrawal Syndrome (NOWS) Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated.
Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4) ] .
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5) ] .
WARNING:
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUPRENORPHINE TRANSDERMAL SYSTEM See full prescribing information for complete boxed warning .
Buprenorphine transdermal system exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death.
Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions.
( 5.1 , 10 ) Serious, life-threatening or fatal respiratory depression may occur, especially upon initiation or following a dosage increase.
To reduce the risk of respiratory depression, proper dosing and titration of buprenorphine transdermal system are essential.
Instruct patients on proper administration of buprenorphine transdermal system to reduce the risk.
( 2.1 , 5.2 ) Accidental exposure to buprenorphine transdermal system, especially in children, can result in fatal overdose of buprenorphine.
( 5.2 ) Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
( 5.3 , 7 ) Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life threatening if not recognized and treated.
Ensure that management by neonatology experts will be available at delivery.
( 5.4 ) Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.
( 5.5 )

Quoted from the official label, section “Boxed Warning”.

Do not take it if

Buprenorphine transdermal system is contraindicated in patients with:
Significant respiratory depression [see Warnings and Precautions (5.2) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.10) ] Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.15) ] Hypersensitivity (e.g., anaphylaxis) to buprenorphine [see Warnings and Precautions (5.18) , Adverse Reactions (6) ] Significant respiratory depression ( 4 ) Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment ( 4 ) Known or suspected gastrointestinal obstruction, including paralytic ileus ( 4 ) Hypersensitivity to buprenorphine ( 4 )

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

Buprenorphine transdermal system should be prescribed only by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks.
( 2.1 ) Buprenorphine transdermal system doses of 7.5, 10, 15, and 20 mcg/hour are only for use in patients receiving, for one week or longer, daily opioid doses up to 80 mg/day of oral morphine or an equianalgesic dose of another opioid.
( 2.1 ) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals.
Reserve titration to higher doses of buprenorphine transdermal system for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.
( 2.1 , 5 ) Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse.
( 2.1 , 5.1 ) Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with buprenorphine transdermal system.
Consider this risk when selecting an initial dose and when making dose adjustments.
(2.1, 5.1 ) For patients who are not opioid tolerant, initiate treatment with a 5 mcg/hour patch.
( 2.1 ) Instruct patients to wear buprenorphine transdermal system for 7 days and to wait a minimum of 3 weeks before applying to the same site.
( 2.1 ) Discuss opioid overdose reversal agents and options for acquiring them with the patient and/or caregiver, both when initiating and renewing treatment with buprenorphine transdermal system, especially if the patient has additional risk factors for overdose, or close contacts at risk for exposure and overdose.
( 2.2 , 5.1 , 5.2 , 5.3 ) Periodically reassess patients receiving buprenorphine transdermal system to evaluate the continued need for opioid analgesics to maintain pain control, for the signs or symptoms of adverse reactions, and for the development of addiction, abuse, or misuse.
( 2.3 ) Do not rapidly reduce or abruptly discontinue buprenorphine transdermal system in a physically dependent patient because rapid reduction or abrupt discontinuation of opioid analgesics has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide.
( 2.5 , 5.19 )
2.1 Important Dosage and Administration Information Buprenorphine transdermal system should be prescribed only by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks.
Buprenorphine transdermal system doses of 7.5, 10, 15, and 20 mcg/hour are only for use in patients who are receiving, for one week or longer, daily opioid doses up to 80 mg/day of oral morphine or an equianalgesic dose of another opioid.
Use the lowest effective dosage for the shortest duration of time consistent with individual patient's treatment goals [see Warnings and Precautions (5) ] .
Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of buprenorphine transdermal system for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks .
Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1) ] .
Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with buprenorphine transdermal system.
Consider this risk when selecting an initial dose and when making dose adjustments [see Warnings and Precautions (5.2) ] .
Buprenorphine transdermal system is for transdermal use (on intact skin) only.
Each buprenorphine transdermal system patch is intended to be worn for 7 days.
Instruct patients not to use buprenorphine transdermal system if the pouch seal is broken or the patch is cut, damaged, or changed in any way and not to cut buprenorphine transdermal system.
Instruct patients to
avoid exposing buprenorphine transdermal system to external heat sources, hot water, or prolonged direct sunlight [see Warnings and Precautions (5.6) ] .
2.2 Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene).
Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose.
The presence of risk factors for overdose should not prevent the management of pain in any patient [see Warnings and Precautions(5.1 , 5.2 , 5.3) ] .
Discuss the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program) [see Warnings and Precautions (5.2) ] .
There are important differences among the opioid overdose reversal agents, such as route of administration, product strength, approved patient age range, and pharmacokinetics.
Be familiar with these differences, as outlined in the approved labeling for those products, prior to recommending or prescribing such an agent.
2.3 Initial Dosage It is safer to underestimate a patient's 24-hour oral buprenorphine dosage and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour buprenorphine dosage and manage an adverse reaction due to an overdose.
While useful tables of opioid equivalents are readily available, there is inter-patient variability in the potency of opioid drugs and opioid formulations.
Frequently reevaluate patients for signs and symptoms of opioid withdrawal and for signs of oversedation/toxicity after converting patients to buprenorphine transdermal system.
Use of Buprenorphine Transdermal System in Patients who are not Opioid Tolerant Unless otherwise listed below, initiate treatment with buprenorphine transdermal system with a 5 mcg/hour patch.
Conversion from Other Opioid Analgesics to Buprenorphine Transdermal System When buprenorphine transdermal system therapy is initiated, discontinue all other opioid analgesics other than those used on an as-needed basis for breakthrough pain when appropriate.
There is a potential for buprenorphine to precipitate withdrawal in patients who are already on opioids.
Prior Total Daily Dose of Opioid Less than 30 mg of Oral Morphine Equivalents per Day :
Initiate treatment with buprenorphine transdermal system 5 mcg/hour at the next dosing interval (see Table 1 below, middle column).
Prior Total Daily Dose of Opioid Between 30 mg to 80 mg of Oral Morphine Equivalents per Day:
Taper the patient's current around-the-clock opioids for up to 7 days to no more than 30 mg of morphine or equivalent per day before beginning treatment with buprenorphine transdermal system.
Then initiate treatment with buprenorphine transdermal system 10 mcg/hour at the next dosing interval (see Table 1 below, right column).
Patients may use short-acting analgesics as needed until analgesic efficacy with buprenorphine transdermal system is attained.
Prior Total Daily Dose of Opioid Greater than 80 mg of Oral Morphine Equivalents per Day :
Buprenorphine transdermal system 20 mcg/hour may not provide adequate analgesia for patients requiring greater than 80 mg/day oral morphine equivalents.
Consider the use of an alternate analgesic.
Table 1:
Initial Buprenorphine Transdermal System Dose Previous Opioid Analgesic Daily Dose (Oral Morphine Equivalent) ≤30 mg 30 to 80 mg ⇩ ⇩ Recommended Buprenorphine Transdermal System Starting Dose 5 mcg/hour 10 mcg/hour Conversion from Methadone to Buprenorphine Transdermal System Regular evaluation is of particular importance when converting from methadone to other opioid agonists.
The ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure.
Methadone has a long half-life and can accumulate in the plasma.
2.4 Titration and Maintenance of Therapy Individually titrate buprenorphine transdermal system to a dose that provides adequate analgesia and minimizes adverse reactions.
Continually reevaluate patients receiving buprenorphine transdermal system to assess the maintenance of pain control, signs and symptoms of opioid withdrawal and other adverse reactions, as well as reassessing for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1 , 5.19) ] .
Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
During use of opioid therapy for an extended period of time, periodically reassess the continued need for opioid analgesics.
The minimum buprenorphine transdermal system titration interval is 72 hours, based on the pharmacokinetic profile and time to reach steady state levels [see Clinical Pharmacology (12.3) ] .
The maximum buprenorphine transdermal system dose is 20 mcg/hour.
Do not exceed a dose of one 20 mcg/hour buprenorphine transdermal system due to the risk of QTc interval prolongation.
In a clinical trial, buprenorphine transdermal system 40 mcg/hour (given as two buprenorphine transdermal system 20 mcg/hour systems) resulted in prolongation of the QTc interval [ see Warnings and Precautions (5.17) , Clinical Pharmacology (12.2) ].
Patients who experience breakthrough pain may require a dosage adjustment increase of buprenorphine transdermal system or may need rescue medication with an appropriate dose of an immediate-release analgesic.
If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the buprenorphine transdermal system dose.
If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after dosage increase) consider reducing the dosage [see Warnings and Precautions (5) ].
Adjust the dosage to obtain an appropriate balance between the management of pain and opioid-related adverse reactions.
Because steady-state plasma concentrations are achieved within 72 hours, buprenorphine transdermal system dosage may be adjusted every 3 days.
Dose adjustments may be made in 5 mcg/hour, 7.5 mcg/hour, or 10 mcg/hour increments by using no more than two patches of the 5 mcg/hour, or 7.5 mcg/hour, or 10 mcg/hour system(s).
The total dose from both patches should not exceed 20 mcg/hour.
For the use of two patches, instruct patients to remove their current patch, and apply the two new patches at the same time, adjacent to one another at a different application site [see Dosage and Administration (2.7) ].
2.5 Safe Reduction or Discontinuation of Buprenorphine Transdermal System Do not rapidly reduce or abruptly discontinue buprenorphine transdermal system in patients who may be physically dependent on opioids.
Rapid reduction or abrupt discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide.
Rapid reduction or abrupt discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.
Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking buprenorphine transdermal system, there are a variety of factors that should be considered, including the total daily dose of opioid (including buprenorphine transdermal system) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.
It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic.
When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder.
Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder.
Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.
There are no standard opioid tapering schedules that are suitable for all patients.
Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually.
For patients on buprenorphine transdermal system who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to
avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.
Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper.
Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge.
Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis.
Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.
If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper.
In addition, evaluate patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.
A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see Warnings and Precautions (5.19) , Drug Abuse and Dependence (9.3) ] .
2.6 Patients with Hepatic Impairment Buprenorphine transdermal system has not been evaluated in patients with severe hepatic impairment.
As buprenorphine transdermal system is only intended for 7-day application, consider use of an alternate analgesic that may permit more flexibility with the dosing in patients with severe hepatic impairment [see Warnings and Precautions (5.14) , Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ].
2.7 Administration of Buprenorphine Transdermal System Instruct patients to apply immediately after removal from the individually sealed pouch.
Instruct patients not to use buprenorphine transdermal system if the pouch seal is broken or the patch is cut, damaged, or changed in any way.
See the Instructions for Use for step-by-step instructions for applying buprenorphine transdermal system.
Apply buprenorphine transdermal system to the upper outer arm, upper chest, upper back, or the side of the chest.
These 4 sites (each present on both sides of the body) provide 8 possible application sites.
Rotate buprenorphine transdermal system among the 8 described skin sites.
After buprenorphine transdermal system removal, wait a minimum of 21 days before reapplying to the same skin site [see Clinical Pharmacology (12.3) ].
Apply buprenorphine transdermal system to a hairless or nearly hairless skin site.
If none are available, the hair at the site should be clipped, not shaven.
Do not apply buprenorphine transdermal system to irritated skin.
If the application site must be cleaned, clean the site with water only.
Do not use soaps, alcohol, oils, lotions, or abrasive devices.
Allow the skin to dry before applying buprenorphine transdermal system.
Incidental exposure of the buprenorphine transdermal system patch to water, such as while bathing or showering, is acceptable based on experience during clinical studies.
If problems with adhesion of buprenorphine transdermal system occur, the edges may be taped with first aid tape.
If problems with lack of adhesion continue, the patch may be covered with waterproof or semipermeable adhesive dressings suitable for 7 days of wear.
If buprenorphine transdermal system falls off during the 7-day dosing interval, dispose of the transdermal system properly and place a new buprenorphine transdermal system patch on at a different skin site.
When changing the system, instruct patients to remove buprenorphine transdermal system and dispose of it properly [see Dosage and Administration (2.8) ] .
If the buprenorphine-containing adhesive matrix accidentally contacts the skin, instruct patients or caregivers to wash the area with water and not to use soap, alcohol, or other solvents to remove the adhesive because they may enhance the absorption of the drug.
2.8 Disposal Instructions Patients should refer to the Instructions for Use for proper disposal of buprenorphine transdermal system.
Dispose of used and unused patches by following the instructions on the Patch-Disposal Unit that is packaged with the buprenorphine transdermal system patches.
Alternatively, patients can dispose of used patches by folding the adhesive side of the patch to itself, then flushing the patch down the toilet immediately upon removal.
Unused patches should be removed from their pouches, the protective liners removed, the patches folded so that the adhesive side of the patch adheres to itself, and immediately flushed down the toilet.
Patients should dispose of any patches remaining from a prescription as soon as they are no longer needed.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain.
If OIH is suspected, carefully consider appropriately decreasing the dose of the current opioid analgesic, or opioid rotation.
( 5.9 ) Life Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients :
Regularly evaluate particularly during initiation and titration.
( 5.10 ) Adrenal Insufficiency :
If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
( 5.11 ) Severe Hypotension : Regularly evaluate during dose initiation and titration.
Avoid use of buprenorphine transdermal system in patients with circulatory shock.
( 5.12 ) Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness :
Monitor for sedation and respiratory depression.
Avoid use of buprenorphine transdermal system in patients with impaired consciousness or coma.
( 5.13 )
5.1 Addiction, Abuse, and Misuse Buprenorphine transdermal system contains buprenorphine, a Schedule III controlled substance.
As an opioid, buprenorphine transdermal system exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9) ] .
Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed buprenorphine transdermal system.
Addiction can occur at recommended doses and if the drug is misused or abused.
The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy.
In postmarketing studies, addiction, abuse, misuse, and fatal and non-fatal opioid overdose were observed in patients with long-term opioid use [see Adverse Reactions (6.2) ] .
Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing buprenorphine transdermal system, and reassess all patients receiving buprenorphine transdermal system for the development of these behaviors and conditions.
Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).
The potential for these risks should not, however, prevent the proper management of pain in any given patient.
Patients at increased risk may be prescribed opioids such as buprenorphine transdermal system but use in such patients necessitates intensive counseling about the risks and proper use of buprenorphine transdermal system, along with frequent reevaluation for signs of addiction, abuse, or misuse.
Abuse or misuse of buprenorphine transdermal system by placing it in the mouth, chewing it, swallowing it, or using it in ways other than indicated may cause choking, overdose, and death [see Overdosage (10) ] .
Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use.
Consider these risks when prescribing or dispensing buprenorphine transdermal system.
Strategies to reduce these risks include prescribing the drug in
the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and the proper disposal of unused drug.
Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
5.2 Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended.
Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death.
Management of respiratory depression may include close observation, supportive measures, and use of opioid overdose reversal agents, depending on the patient's clinical status [see Overdosage (10) ] .
Carbon dioxide (CO 2 ) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.
While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of buprenorphine transdermal system, the risk is greatest during the initiation of therapy or following a dosage increase.
To reduce the risk of respiratory depression, proper dosing and titration of buprenorphine transdermal system are essential [see Dosage and Administration (2) ] .
Overestimating the buprenorphine transdermal system dosage when converting patients from another opioid product can result in fatal overdose with the first dose.
Accidental exposure to buprenorphine transdermal system, especially in children, can result in respiratory depression and death due to an overdose of buprenorphine.
Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia.
Opioid use increases the risk of CSA in a dose-dependent fashion.
In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration (2.5) ].
The presence of risk factors for overdose should not prevent the management of pain in any patient [see Warnings and Precautions (5.1 , 5.3) ] .
Educate patients and caregivers on how to recognize respiratory depression, and how to use an opioid overdose reversal agent for the emergency treatment of opioid overdose.
Emphasize the importance of calling 911 or getting emergency medical help, even if an opioid overdose reversal agent is administered [see Dosage and Administration (2.2) , Warnings and Precautions (5.1 , 5.3) , Overdosage (10) ].
5.3 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of buprenorphine transdermal system with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin and pregabalin], and other opioids).
Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone.
Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions (7) ] .
If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use.
In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response.
If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response.
If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) , Overdosage (10) ] .
Advise both patients and caregivers about the risks of respiratory depression and sedation when buprenorphine transdermal system is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs).
Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined.
Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions (7) , Patient Counseling Information (17) ] .
5.4 Neonatal Opioid Withdrawal Syndrome Use of buprenorphine transdermal system for an extended period of time during pregnancy can result in withdrawal in the neonate.
Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in
adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.
Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly.
Advise pregnant women using opioids for an extended period of time of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Use in Specific Populations (8.1) ] .
5.5 Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products.
Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers.
Healthcare providers are strongly encouraged to do all of the following:
Complete a REMS-compliant education program offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain.
Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed.
The Patient Counseling Guide (PCG) can be obtained at this link:
www.fda.gov/OpioidAnalgesicREMSPCG.
Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them.
Consider using other tools to improve patient, household, and community safety, such as patient-prescriber agreements that reinforce patient-prescriber responsibilities.
To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com.
The FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint.
5.6 Risks of Use with Application of External Heat Advise patients and their caregivers to
avoid exposing the buprenorphine transdermal system application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, saunas, hot tubs, and heated water beds while wearing the system because an increase in absorption of buprenorphine may occur [see Clinical Pharmacology (12.3) ] .
Advise patients against exposure of the buprenorphine transdermal system application site and surrounding area to hot water or prolonged exposure to direct sunlight.
There is a potential for temperature-dependent increases in buprenorphine released from the system resulting in possible overdose and death.
5.7 Risk of Use in Patients with Fever Regularly evaluate patients wearing buprenorphine transdermal systems who develop fever or increased core body temperature due to strenuous exertion for opioid side effects and adjust the buprenorphine transdermal system dose if signs of respiratory or central nervous system depression occur.
5.8 Application Site Skin Reactions In rare cases, severe application site skin reactions with signs of marked inflammation including "burn," "discharge," and "vesicles" have occurred.
Time of onset varies, ranging from days to months following the initiation of buprenorphine transdermal system treatment.
Instruct patients to promptly report the development of severe application site reactions and discontinue therapy.
5.9 Opioid-Induced Hyperalgesia and Allodynia Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain.
This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect [see Drug Abuse and Dependence (9.3) ] .
Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia).
These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.
Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics.
Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated.
Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia.
If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) [see Dosage and Administration (2.5) , Warnings and Precautions (5.19) ].
5.10 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients The use of buprenorphine transdermal system in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.
Patients with Chronic Pulmonary Disease:
Buprenorphine transdermal system-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of buprenorphine transdermal system [see Warnings and Precautions (5.2) ].
Elderly, Cachectic, or Debilitated Patients:
Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see Warnings and Precautions (5.2) ].
Regularly evaluate patients particularly when initiating and titrating buprenorphine transdermal system and when buprenorphine transdermal system is given concomitantly with other drugs that depress respiration [see Warnings and Precautions (5.2 , 5.3) , Drug Interactions (7) ] .
Alternatively, consider the use of non-opioid analgesics in these patients.
5.11 Adrenal Insufficiency Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.
Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure.
If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible.
If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids.
Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers.
Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency.
The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.
5.12 Severe Hypotension Buprenorphine transdermal system may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients.
There is an increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see Drug Interactions (7) ] .
Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of buprenorphine transdermal system.
In patients with circulatory shock, buprenorphine transdermal system may cause vasodilation that can further reduce cardiac output and blood pressure.
Avoid the use of buprenorphine transdermal system in patients with circulatory shock.
5.13 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness In patients who may be susceptible to the intracranial effects of CO 2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), buprenorphine transdermal system may reduce respiratory drive, and the resultant CO 2 retention can further increase intracranial pressure.
Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with buprenorphine transdermal system.
Opioids may also obscure the clinical course in a patient with a head injury.
Avoid the use of buprenorphine transdermal system in patients with impaired consciousness or coma.
5.14 Hepatotoxicity Cases of cytolytic hepatitis and hepatitis with jaundice have been observed in individuals receiving sublingual buprenorphine for the treatment of opioid dependence, both in clinical trials and in post-marketing adverse event reports.
The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports of hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy.
In many cases, the presence of pre-existing liver enzyme abnormalities, infection with hepatitis B or hepatitis C virus, concomitant usage of other potentially hepatotoxic drugs, and ongoing injection drug abuse may have played a causative or contributory role.
For patients at increased risk of hepatotoxicity (e.g., patients with a history of excessive alcohol intake, intravenous drug abuse, or liver disease), obtain baseline liver enzyme levels and monitor periodically and during treatment with buprenorphine transdermal system.
5.15 Risks of Gastrointestinal Complications Buprenorphine transdermal system is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
The buprenorphine in buprenorphine transdermal system may cause spasm of the sphincter of Oddi.
Opioids may cause increases in the serum amylase.
Regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
Cases of opioid-induced esophageal dysfunction (OIED) have been reported in patients taking opioids.
The risk of OIED may increase as the dose and/or duration of opioids increases.
Regularly evaluate patients for signs and symptoms of OIED (e.g., dysphagia, regurgitation, non-cardiac chest pain) and, if necessary, adjust opioid therapy as clinically appropriate [see Clinical Pharmacology (12.2) ] .
5.16 Increased Risk of Seizures in Patients with Seizure Disorders The buprenorphine in buprenorphine transdermal system may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures in other clinical settings associated with seizures.
Regularly evaluate patients with a history of seizure disorders for worsened seizure control during buprenorphine transdermal system therapy.
5.17 QTc Prolongation Thorough QT studies with buprenorphine products have demonstrated QT prolongation ≤15 msec.
This QTc prolongation effect does not appear to be mediated by hERG channels.
Based on these two findings, buprenorphine is unlikely to be pro-arrhythmic when used alone in patients without risk factors.
The risk of combining buprenorphine with other QT-prolonging agents is not known.
Consider these observations in clinical decisions when prescribing buprenorphine transdermal system to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia.
5.18 Anaphylactic/Allergic Reactions Cases of acute and chronic hypersensitivity to buprenorphine have been reported both in clinical trials and in the post-marketing experience.
The most common signs and symptoms include rashes, hives, and pruritus.
Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported.
A history of hypersensitivity to buprenorphine is a contraindication to the use of buprenorphine transdermal system.
5.19 Withdrawal Do not rapidly reduce or abruptly discontinue buprenorphine in a patient physically dependent on opioids.
When discontinuing buprenorphine transdermal system in a physically dependent patient, gradually taper the dosage.
Rapid tapering of buprenorphine in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain [see Dosage and Administration (2.5) , Drug Abuse and Dependence (9.3) ] .
Additionally, the use of buprenorphine transdermal system, a partial agonist opioid analgesic, in patients who are receiving a full opioid agonist analgesic may reduce the analgesic effect and/or precipitate withdrawal symptoms.
Avoid concomitant use of buprenorphine transdermal system with a full opioid agonist analgesic.
5.20 Risks of Driving and Operating Machinery Buprenorphine transdermal system may impair the mental and physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery.
Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of buprenorphine transdermal system and know how they will react to the medication.
5.21 Use in Addiction Treatment Buprenorphine transdermal system has not been studied and is not approved for use in the management of addictive disorders.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Risk Summary Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome [see Warnings and Precautions (5.4) ].
Available data with buprenorphine transdermal system in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.
In animal reproduction studies, buprenorphine caused an increase in the number of stillborn offspring, reduced litter size, and reduced offspring growth in rats at maternal exposure levels that were approximately 10 times that of human subjects who received one buprenorphine transdermal system 20 mcg/hour, the maximum recommended human dose (MRHD) [see Data ].
Based on animal data, advise pregnant women of the potential risk to a fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Fetal/neonatal adverse reactions Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.
Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.
The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn.
Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see Warnings and Precautions (5.4) ].
Labor and Delivery Opioids cross the placenta and may produce respiratory depression and psychophysiologic effects in neonates.
An opioid overdose reversal agent, such as naloxone or nalmefene, must be available for reversal of opioid-induced respiratory depression in the neonate.
Buprenorphine transdermal system is not recommended for use in women immediately prior to labor, when shorter acting analgesics or other analgesic techniques are more appropriate.
Opioid analgesics, including buprenorphine transdermal system, can prolong labor through actions that temporarily reduce the strength, duration, and frequency of uterine contractions.
However, this effect is not consistent and may be offset by an increased rate of cervical dilatation, which tends to shorten labor.
Data Animal Data Studies in rats and rabbits demonstrated no evidence of teratogenicity following buprenorphine transdermal system or subcutaneous (SC) administration of buprenorphine during the period of organogenesis.
Rats were administered up to one buprenorphine transdermal system 20 mcg/hour every 3 days (Gestation Days 6, 9, 12, & 15) or received daily SC buprenorphine up to 5 mg/kg (Gestation Days 6 to 17).
Rabbits were administered four buprenorphine transdermal system 20 mcg/hour every 3 days (Gestation Days 6, 9, 12, 15, 18, and 19) or received daily SC buprenorphine up to 5 mg/kg (Gestation Days 6 to 19).
No teratogenicity was observed at any dose.
AUC values for buprenorphine with buprenorphine transdermal system application and SC injection were approximately 110 and 140 times, respectively, that of human subjects who received the MRHD of one buprenorphine transdermal system 20 mcg/hour.
In a pre- and post-natal study conducted in pregnant and lactating rats, administration of buprenorphine either as buprenorphine transdermal system or SC buprenorphine was associated with toxicity to offspring.
Buprenorphine was present in maternal milk.
Pregnant rats were administered 1/4 of one buprenorphine transdermal system 5 mcg/hour every 3 days or received daily SC buprenorphine at doses of 0.05, 0.5, or 5 mg/kg from Gestation Day 6 to Lactation Day 21 (weaning).
Administration of buprenorphine transdermal system or SC buprenorphine at 0.5 or 5 mg/kg caused maternal toxicity and an increase in the number of stillborns, reduced litter size, and reduced offspring growth at maternal exposure levels that were approximately 10 times that of human subjects who received the MRHD of one buprenorphine transdermal system 20 mcg/hour.
Maternal toxicity was also observed at the no observed adverse effect level (NOAEL) for offspring.
IN SPECIFIC POPULATIONS Pregnancy : May cause fetal harm.
( 8.1 ) Lactation : Not recommended.
( 8.2 ) Severe Hepatic Impairment :
Consider use of an alternate analgesic that may permit more flexibility in dosing.
( 8.6 )
8.1 Pregnancy Risk Summary Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome [see Warnings and Precautions (5.4) ].
Available data with buprenorphine transdermal system in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.
In animal reproduction studies, buprenorphine caused an increase in the number of stillborn offspring, reduced litter size, and reduced offspring growth in rats at maternal exposure levels that were approximately 10 times that of human subjects who received one buprenorphine transdermal system 20 mcg/hour, the maximum recommended human dose (MRHD) [see Data ].
Based on animal data, advise pregnant women of the potential risk to a fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Fetal/neonatal adverse reactions Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.
Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.
The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn.
Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see Warnings and Precautions (5.4) ].
Labor and Delivery Opioids cross the placenta and may produce respiratory depression and psychophysiologic effects in neonates.
An opioid overdose reversal agent, such as naloxone or nalmefene, must be available for reversal of opioid-induced respiratory depression in the neonate.
Buprenorphine transdermal system is not recommended for use in women immediately prior to labor, when shorter acting analgesics or other analgesic techniques are more appropriate.
Opioid analgesics, including buprenorphine transdermal system, can prolong labor through actions that temporarily reduce the strength, duration, and frequency of uterine contractions.
However, this effect is not consistent and may be offset by an increased rate of cervical dilatation, which tends to shorten labor.
Data Animal Data Studies in rats and rabbits demonstrated no evidence of teratogenicity following buprenorphine transdermal system or subcutaneous (SC) administration of buprenorphine during the period of organogenesis.
Rats were administered up to one buprenorphine transdermal system 20 mcg/hour every 3 days (Gestation Days 6, 9, 12, & 15) or received daily SC buprenorphine up to 5 mg/kg (Gestation Days 6 to 17).
Rabbits were administered four buprenorphine transdermal system 20 mcg/hour every 3 days (Gestation Days 6, 9, 12, 15, 18, and 19) or received daily SC buprenorphine up to 5 mg/kg (Gestation Days 6 to 19).
No teratogenicity was observed at any dose.
AUC values for buprenorphine with buprenorphine transdermal system application and SC injection were approximately 110 and 140 times, respectively, that of human subjects who received the MRHD of one buprenorphine transdermal system 20 mcg/hour.
In a pre- and post-natal study conducted in pregnant and lactating rats, administration of buprenorphine either as buprenorphine transdermal system or SC buprenorphine was associated with toxicity to offspring.
Buprenorphine was present in maternal milk.
Pregnant rats were administered 1/4 of one buprenorphine transdermal system 5 mcg/hour every 3 days or received daily SC buprenorphine at doses of 0.05, 0.5, or 5 mg/kg from Gestation Day 6 to Lactation Day 21 (weaning).
Administration of buprenorphine transdermal system or SC buprenorphine at 0.5 or 5 mg/kg caused maternal toxicity and an increase in the number of stillborns, reduced litter size, and reduced offspring growth at maternal exposure levels that were approximately 10 times that of human subjects who received the MRHD of one buprenorphine transdermal system 20 mcg/hour.
Maternal toxicity was also observed at the no observed adverse effect level (NOAEL) for offspring.
8.2 Lactation Risk Summary Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with buprenorphine transdermal system.
Clinical Considerations Monitor infants exposed to buprenorphine transdermal system through breast milk for excess sedation and respiratory depression.
Withdrawal symptoms can occur in breastfed infants when maternal administration of buprenorphine is stopped or when breastfeeding is stopped.
8.3 Females and Males of Reproductive Potential Infertility Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential.
It is not known whether these effects on fertility are reversible [see Adverse Reactions (6.2) , Clinical Pharmacology (12.2) , Nonclinical Toxicology (13.1) ] .
8.4 Pediatric Use The safety and efficacy of buprenorphine transdermal system in patients under 18 years of age have not been established.
Buprenorphine transdermal system has been evaluated in an open-label clinical trial in pediatric patients.
However, definitive conclusions are not possible because of the small sample size.
8.5 Geriatric Use Of the total number of subjects in the clinical trials (5,415), buprenorphine transdermal system was administered to 1,377 patients aged 65 years and older.
Of those, 457 patients were 75 years of age and older.
In the clinical program, the incidences of selected buprenorphine transdermal system-related AEs were higher in older subjects.
The incidences of application site AEs were slightly higher among subjects <65 years of age than those ≥65 years of age for both buprenorphine transdermal system and placebo treatment groups.
In a single-dose study of healthy elderly and healthy young subjects treated with buprenorphine transdermal system 10 mcg/hour, the pharmacokinetics were similar.
In a separate dose-escalation safety study, the pharmacokinetics in the healthy elderly and hypertensive elderly subjects taking thiazide diuretics were similar to those in the healthy young
adults.
In the elderly groups evaluated, adverse event rates were similar to or lower than rates in healthy young adult subjects, except for constipation and urinary retention, which were more common in the elderly.
Although specific dose adjustments on the basis of advanced age are not required for pharmacokinetic reasons, use caution in the elderly population to ensure safe use [see Clinical Pharmacology (12.3) ] .
Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration.
Titrate the dosage of buprenorphine transdermal system slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.10) ] .
8.6 Hepatic Impairment In a study utilizing intravenous buprenorphine, peak plasma levels (C max ) and exposure (AUC) of buprenorphine in patients with mild and moderate hepatic impairment did not increase as compared to those observed in subjects with normal hepatic function.
Buprenorphine transdermal system has not been evaluated in patients with severe hepatic impairment.
As buprenorphine transdermal system is intended for 7-day dosing, consider the use of alternate analgesic therapy in patients with severe hepatic impairment [see Dosage and Administration (2.6) , Clinical Pharmacology (12.3) ].

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Table 5 includes clinically significant drug interactions with buprenorphine transdermal system.
Table 5:
Clinically Significant Drug Interactions with Buprenorphine Transdermal System Benzodiazepines Clinical Impact:
There have been a number of reports regarding coma and death associated with the misuse and abuse of the combination of buprenorphine and benzodiazepines.
In many, but not all of these cases, buprenorphine was misused by self-injection of crushed buprenorphine tablets.
Preclinical studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists.
Intervention:
Regularly evaluate patients with concurrent use of buprenorphine transdermal system and benzodiazepines.
Warn patients that it is extremely dangerous to self-administer benzodiazepines while taking buprenorphine transdermal system, and warn patients to use benzodiazepines concurrently with buprenorphine transdermal system only as directed by their physician.
Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact:
Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death [see Warnings and Precautions (5.3) ] .
Intervention:
Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
Limit dosages and durations to the minimum required.
Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation).
If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent [see Dosage and Administration (2.2) , Warnings and Precautions (5.1 , 5.2 , 5.3) ] .
Examples:
Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol.
Inhibitors of CYP3A4 Clinical Impact:
The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine transdermal system is achieved.
After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the buprenorphine plasma concentration will decrease [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to buprenorphine.
Intervention:
If concomitant use is necessary, consider dosage reduction of buprenorphine transdermal system until stable drug effects are achieved.
Evaluate patients at frequent intervals for respiratory depression and sedation.
If a CYP3A4 inhibitor is discontinued, consider increasing the buprenorphine transdermal system dosage until stable drug effects are achieved.
Assess for signs of opioid withdrawal.
Examples:
Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact:
The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine.
After stopping a CYP3A4 inducer, as the effects of the inducer decline, the buprenorphine plasma concentration will increase [see Clinical Pharmacology (12.3) ] , which could increase or prolong both therapeutic effects and adverse reactions and may cause serious respiratory depression.
Intervention:
If concomitant use is necessary, consider increasing the buprenorphine transdermal system dosage until stable drug effects are achieved.
Assess for signs of opioid withdrawal.
If a CYP3A4 inducer is discontinued, consider buprenorphine transdermal system dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation.
Examples:
Rifampin, carbamazepine, phenytoin Serotonergic Drugs Clinical Impact:
The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.
Intervention:
If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment.
Discontinue buprenorphine transdermal system if serotonin syndrome is suspected.
Examples:
Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact:
MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ] Intervention:
The use of buprenorphine transdermal system is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
Examples:
phenelzine, tranylcypromine, linezolid Mixed Agonist/Antagonist Opioid Analgesics Clinical Impact:
May reduce the analgesic effect of buprenorphine transdermal system and/or precipitate withdrawal symptoms.
Intervention: Avoid concomitant use.
Examples:
butorphanol, nalbuphine, pentazocine Muscle Relaxants Clinical Impact:
Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
Intervention:
Because respiratory depression may be greater than otherwise expected, decrease the dosage of buprenorphine transdermal system and/or the muscle relaxant as necessary.
Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider recommending or prescribing an opioid overdose reversal agent [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ].
Examples:
Cyclobenzaprine, metaxalone Diuretics Clinical Impact:
Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.
Intervention:
Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
Anticholinergic Drugs Clinical Impact:
The concomitant use of opioid analgesics, including buprenorphine, and anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
Intervention:
Evaluate patients for signs of urinary retention or reduced gastric motility when buprenorphine transdermal system is used concomitantly with anticholinergic drugs.
Benzodiazepines : May increase buprenorphine-induced respiratory depression.
Frequently evaluate patients on concurrent therapy closely.
( 7 ) CYP3A4 Inhibitors/Inducers :
Initiating CYP3A4 inhibitors or discontinuing CYP3A4 inducers may result in an increase in buprenorphine plasma concentrations.
Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression.
( 7 ) Serotonergic Drugs : Concomitant use may result in serotonin syndrome.
Discontinue buprenorphine transdermal system if serotonin syndrome is suspected.
( 7 ) Mixed Agonist/Antagonist Analgesics :
Avoid use with buprenorphine transdermal system because they may reduce analgesic effect of buprenorphine transdermal system or precipitate withdrawal symptoms.
( 7 )

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Clinical Presentation Acute overdosage with buprenorphine is manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death.
Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations [see Clinical Pharmacology (12.2) ] .
Toxic leukoencephalopathy has been reported after opioid overdose and can present hours, days, or weeks after apparent recovery from the initial intoxication.
Treatment of Overdose In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed.
Employ other supportive measures (including oxygen, vasopressors) in the management of circulatory shock and pulmonary edema as indicated.
Cardiac arrest or arrhythmias will require advanced life support measures.
Naloxone may not be effective in reversing any respiratory depression produced by buprenorphine.
High doses of naloxone, 10 to 35 mg/70 kg, may be of limited value in the management of buprenorphine overdose.
The onset of naloxone effect may be delayed by 30 minutes or more.
Remove buprenorphine transdermal system immediately.
Because the duration of reversal would be expected to be less than the duration of action of buprenorphine from buprenorphine transdermal system, carefully monitor the patient until spontaneous respiration is reliably re-established.
Even in the face of improvement, continued medical monitoring is required because of the possibility of extended effects as buprenorphine continues to be absorbed from the skin.
After removal of buprenorphine transdermal system, the mean buprenorphine concentrations decrease approximately 50% in 12 hours (range 10 to 24 hours) with an apparent terminal half-life of approximately 26 hours.
Due to this long apparent terminal half-life, patients may require monitoring and treatment for at least 24 hours.
In an individual physically dependent on opioids, administration of an opioid overdose reversal agent may precipitate an acute withdrawal syndrome.
The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the reversal agent administered.
If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the reversal agent should begin with care and by titration with smaller than usual doses of the reversal agent.

Quoted from the official label, section “Overdosage”.

Misuse and dependence

9.1 Controlled Substance Buprenorphine transdermal system contains buprenorphine, a Schedule III controlled substance.
9.2 Abuse Buprenorphine transdermal system contains buprenorphine, a substance with high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see Warnings and Precautions (5.1) ] .
Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed.
Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.
Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.
Misuse and abuse of buprenorphine transdermal system increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death.
The risk is increased with concurrent abuse of buprenorphine transdermal system with alcohol and/or other CNS depressants.
Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence.
In addition, abuse of opioids can occur in the absence of addiction.
All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.
Patients at high risk of buprenorphine transdermal system abuse include those with a history of prolonged use of any opioid, including products containing buprenorphine, those with a history of drug or alcohol abuse, or those who use buprenorphine transdermal system in combination with other abused drugs. "Drug-seeking" behavior is very common in persons with substance use disorders.
Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated "loss" of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). "Doctor shopping" (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder.
Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control.
Buprenorphine transdermal system, like other opioids, can be diverted for nonmedical use into illicit channels of distribution.
Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.
Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
Risks Specific to Abuse of Buprenorphine Transdermal System Abuse of buprenorphine transdermal system poses a risk of overdose and death.
This risk is increased with the concurrent use of buprenorphine transdermal system with alcohol and/or other substances including other opioids and benzodiazepines [see Warnings and Precautions (5.1 , 5.3) , Drug Interactions (7) ] .
Buprenorphine transdermal system is approved for transdermal use only.
Intentional compromise of the transdermal delivery system will result in the uncontrolled delivery of buprenorphine and pose a significant risk to the abuser that could result in overdose and death [see Warnings and Precautions (5.1) ] .
Abuse may occur by applying the transdermal system in the absence of legitimate purpose, or by chewing, swallowing, snorting, or injecting buprenorphine extracted from the transdermal system.
Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
9.3 Dependence Both tolerance and physical dependence can develop during use of opioid therapy.
Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).
Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.
Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine).
Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.
Do not rapidly reduce or abruptly discontinue buprenorphine transdermal system in a patient physically dependent on opioids.
Rapid tapering of buprenorphine transdermal system in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide.
Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.
When discontinuing buprenorphine transdermal system, gradually taper the dosage using a patient-specific plan that considers the following:
the dose of buprenorphine transdermal system the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient.
To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient.
In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see Dosage and Administration (2.1) , Warnings and Precautions (5.19) ] .
Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations (8.1) ] .
Buprenorphine transdermal system contains buprenorphine, a Schedule III controlled substance.

Quoted from the official label, section “Drug Abuse and Dependence”.

Use in children

The safety and efficacy of buprenorphine transdermal system in patients under 18 years of age have not been established.
Buprenorphine transdermal system has been evaluated in an open-label clinical trial in pediatric patients.
However, definitive conclusions are not possible because of the small sample size.

Quoted from the official label, section “Pediatric Use”.

Use in older people

Of the total number of subjects in the clinical trials (5,415), buprenorphine transdermal system was administered to 1,377 patients aged 65 years and older.
Of those, 457 patients were 75 years of age and older.
In the clinical program, the incidences of selected buprenorphine transdermal system-related AEs were higher in older subjects.
The incidences of application site AEs were slightly higher among subjects <65 years of age than those ≥65 years of age for both buprenorphine transdermal system and placebo treatment groups.
In a single-dose study of healthy elderly and healthy young subjects treated with buprenorphine transdermal system 10 mcg/hour, the pharmacokinetics were similar.
In a separate dose-escalation safety study, the pharmacokinetics in the healthy elderly and hypertensive elderly subjects taking thiazide diuretics were similar to those in the healthy young
adults.
In the elderly groups evaluated, adverse event rates were similar to or lower than rates in healthy young adult subjects, except for constipation and urinary retention, which were more common in the elderly.
Although specific dose adjustments on the basis of advanced age are not required for pharmacokinetic reasons, use caution in the elderly population to ensure safe use [see Clinical Pharmacology (12.3) ] .
Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration.
Titrate the dosage of buprenorphine transdermal system slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.10) ] .

Quoted from the official label, section “Geriatric Use”.

Side effects

The following serious adverse reactions are described elsewhere in the labeling:
Addiction, Abuse, and Misuse [see Warnings and Precautions (5.1) ] Life-Threatening Respiratory Depression [see Warnings and Precautions (5.2) ] Interactions with Benzodiazepines or Other CNS Depressants [see Warnings and Precautions (5.3) ] Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.4) ] Application Site Skin Reactions [see Warnings and Precautions (5.8) ] Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions (5.9) ] Adrenal Insufficiency [see Warnings and Precautions (5.11) ] Severe Hypotension [see Warnings and Precautions (5.12) ] Hepatotoxicity [see Warnings and Precautions (5.14) ] Gastrointestinal Effects [see Warnings and Precautions (5.15) ] Seizures [see Warnings and Precautions (5.16) ] QTc Prolongation [see Warnings and Precautions (5.17) ] Anaphylactic/Allergic Reactions [see Warnings and Precautions (5.18) ] Most common adverse reactions (≥5%) include:
nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Rhodes Pharmaceuticals LLC at 1-888-873-5329 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 5,415 patients were treated with buprenorphine transdermal system in controlled and open-label chronic pain clinical trials.
Nine hundred twenty-four subjects were treated for approximately six months and 183 subjects were treated for approximately one year.
The clinical trial population consisted of patients with persistent moderate to severe pain.
The most common serious adverse drug reactions (all <0.1%) occurring during clinical trials with buprenorphine transdermal system were:
chest pain, abdominal pain, vomiting, dehydration, and hypertension/blood pressure increased.
The most common adverse events (≥2%) leading to discontinuation were:
nausea, dizziness, vomiting, headache, and somnolence.
The most common adverse reactions (≥5%) reported by patients in clinical trials comparing buprenorphine transdermal system 10 or 20 mcg/hour to placebo are shown in Table 2, and comparing buprenorphine transdermal system 20 mcg/hour to buprenorphine transdermal system 5 mcg/hour are shown in Table 3 below:
Table 2:
Adverse Reactions Reported in ≥5% of Patients during the Open-Label Titration Period and Double-Blind Treatment Period:
Patients who were not Opioid Tolerant Open-Label Titration Period Double-Blind Treatment Period Buprenorphine Transdermal System Buprenorphine Transdermal System Placebo MedDRA Preferred Term (N = 1024) (N = 256) (N = 283) Nausea 23% 13% 10% Dizziness 10% 4% 1% Headache 9% 5% 5% Application site pruritus 8% 4% 7% Somnolence 8% 2% 2% Vomiting 7% 4% 1% Constipation 6% 4% 1% Table 3:
Adverse Reactions Reported in ≥5% of Patients during the Open-Label Titration Period and Double-Blind Treatment Period:
Opioid-Experienced Patients Open-Label Titration Period Double-Blind Treatment Period Buprenorphine Transdermal System Buprenorphine Transdermal System 20 Buprenorphine Transdermal System 5 MedDRA Preferred Term (N = 1160) (N = 219) (N = 221) Nausea 14% 11% 6% Application site pruritus 9% 13% 5% Headache 9% 8% 3% Somnolence 6% 4% 2% Dizziness 5% 4% 2% Constipation 4% 6% 3% Application site erythema 3% 10% 5% Application site rash 3% 8% 6% Application site irritation 2% 6% 2% The following table lists adverse reactions that were reported in at least 2.0% of patients in four placebo/active-controlled titration-to-effect trials.
Table 4:
Adverse Reactions Reported in Titration-to-Effect Placebo/Active-Controlled Clinical Trials with Incidence ≥2% MedDRA Preferred Term Buprenorphine Transdermal System (N = 392) Placebo (N = 261) Nausea 21% 6% Application site pruritus 15% 12% Dizziness 15% 7% Headache 14% 9% Somnolence 13% 4% Constipation 13% 5% Vomiting 9% 1% Application site erythema 7% 2% Application site rash 6% 6% Dry mouth 6% 2% Fatigue 5% 1% Hyperhidrosis 4% 1% Peripheral edema 3% 1% Pruritus 3% 0% Stomach discomfort 2% 0% The adverse reactions seen in controlled and open-label studies are presented below in the following manner:
most common (≥5%), common (≥1% to <5%), and less common (<1%).
The most common adverse reactions (≥5%) reported by patients treated with buprenorphine transdermal system in the clinical trials were nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.
The common (≥1% to <5%) adverse reactions reported by patients treated with buprenorphine transdermal system in the clinical trials organized by MedDRA (Medical Dictionary for Regulatory Activities) System Organ Class were:
Gastrointestinal disorders :
diarrhea, dyspepsia, and upper abdominal pain General disorders and administration site conditions :
fatigue, peripheral edema, application site irritation, pain, pyrexia, chest pain, and asthenia Infections and infestations :
urinary tract infection, upper respiratory tract infection, nasopharyngitis, influenza, sinusitis, and bronchitis Injury, poisoning, and procedural complications :
fall Metabolism and nutrition disorders :
anorexia Musculoskeletal and connective tissue disorders :
back pain, arthralgia, pain in extremity, muscle spasms, musculoskeletal pain, joint swelling, neck pain, and myalgia Nervous system disorders :
hypoesthesia, tremor, migraine, and paresthesia Psychiatric disorders :
insomnia, anxiety, and depression Respiratory, thoracic, and mediastinal disorders :
dyspnea, pharyngolaryngeal pain, and cough Skin and subcutaneous tissue disorders :
pruritus, hyperhidrosis, rash, and generalized pruritus Vascular disorders :
hypertension Other less common adverse reactions, including those known to occur with opioid treatment, that were seen in <1% of the patients in the buprenorphine transdermal system trials include the following in alphabetical order:
Abdominal distention, abdominal pain, accidental injury, affect lability, agitation, alanine aminotransferase increased, angina pectoris, angioedema, apathy, application site dermatitis, asthma aggravated, bradycardia, chills, confusional state, contact dermatitis, coordination abnormal, dehydration, depersonalization, depressed level of consciousness, depressed mood, disorientation, disturbance in attention, diverticulitis, drug hypersensitivity, drug withdrawal syndrome, dry eye, dry skin, dysarthria, dysgeusia, dysphagia, euphoric mood, face edema, flatulence, flushing, gait disturbance, hallucination, hiccups, hot flush, hyperventilation, hypotension, hypoventilation, ileus, insomnia, libido decreased, loss of consciousness, malaise, memory impairment, mental impairment, mental status changes, miosis, muscle weakness, nervousness, nightmare, orthostatic hypotension, palpitations, psychotic disorder, respiration abnormal, respiratory depression, respiratory distress, respiratory failure, restlessness, rhinitis, sedation, sexual dysfunction, syncope, tachycardia, tinnitus, urinary hesitation, urinary incontinence, urinary retention, urticaria, vasodilatation, vertigo, vision blurred, visual disturbance, weight decreased, and wheezing.
6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of buprenorphine.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Serotonin syndrome :
Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.
Adrenal insufficiency :
Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.
Anaphylaxis :
Anaphylaxis has been reported with ingredients contained in buprenorphine transdermal system.
Androgen deficiency :
Cases of androgen deficiency have occurred with use of opioids for an extended period of time [see Clinical Pharmacology (12.2) ] .
Hyperalgesia and Allodynia :
Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see Warnings and Precautions (5.9) ].
Hypoglycemia : Cases of hypoglycemia have been reported in patients taking opioids.
Most reports were in patients with at least one predisposing risk factor (e.g., diabetes).
Opioid-induced esophageal dysfunction (OIED ):
Cases of OIED have been reported in patients taking opioids and may occur more frequently in patients taking higher doses of opioids, and/or in patients taking opioids longer term [see Warnings and Precautions (5.15) ].
Adverse Reactions from Observational Studies A prospective, observational cohort study estimated the risks of addiction, abuse, and misuse in patients initiating long-term use of Schedule II opioid analgesics between 2017 and 2021.
Study participants included in one or more analyses had been enrolled in selected insurance plans or health systems for at least one year, were free of at least one outcome at baseline, completed a minimum number of follow-up assessments, and either:
1) filled multiple extended-release/long-acting opioid analgesic prescriptions during a 90-day period (n=978); or 2) filled any Schedule II opioid analgesic prescriptions covering at least 70 of 90 days (n=1,244).
Those included also had no dispensing of the qualifying opioids in the previous 6 months.
Over 12 months:
approximately 1% to 6% of participants across the two cohorts newly met criteria for addiction, as assessed with two validated interview-based measures of moderate-to-severe opioid use disorder based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, and approximately 9% and 22% of participants across the two cohorts newly met criteria for prescription opioid abuse and misuse [defined in Drug Abuse and Dependence (9.2)], respectively, as measured with a validated self-reported instrument.
A retrospective, observational cohort study estimated the risk of opioid- involved overdose or opioid overdose-related death in patients with new long-term use of Schedule II opioid analgesics from 2006 through 2016 (n=220,249).
Included patients had been enrolled in either one of two commercial insurance programs, one managed care program, or one Medicaid program for at least 9 months.
New long-term use was defined as having Schedule II opioid analgesic prescriptions covering at least 70 days' supply over the 3 months prior to study entry and none during the preceding 6 months.
Patients were excluded if they had an opioid-involved overdose in the 9 months prior to study entry.
Overdose was measured using a validated medical code-based algorithm with linkage to the National Death Index database.
The 5-year cumulative incidence estimates for opioid-involved overdose or opioid overdose-related death ranged from approximately 1.5% to 4% across study sites, counting only the first event during follow-up.
Approximately 17% of first opioid overdoses observed over the entire study period (5 to11 years, depending on the study site) were fatal.
Higher baseline opioid dose was the strongest and most consistent predictor of opioid-involved overdose or opioid overdose-related death.
Study exclusion criteria may have selected patients at lower risk of overdose, and substantial loss to follow-up (approximately 80%) also may have biased estimates.
The risk estimates from the studies described above may not be generalizable to all patients receiving opioid analgesics, such as those with exposures shorter or longer than the duration evaluated in the studies.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Storage and Disposal Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store buprenorphine transdermal system securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.
Inform patients that leaving buprenorphine transdermal system unsecured can pose a deadly risk to others in the home [see Warnings and Precautions (5.1 , 5.2) , Drug Abuse and Dependence (9.2) ] .
Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly.
Buprenorphine transdermal system patches can be disposed of by using the Patch-Disposal Unit [see Instructions for Use ].
Alternatively, expired, unwanted, or unused buprenorphine transdermal system should be disposed of by folding the patch in half and flushing the unused medication down the toilet if a drug take-back option is not readily available.
Inform patients that they can visit www.fda.gov/drugdisposal for a complete list of medicines recommended for disposal by flushing, as well as additional information on disposal of unused medicines.
Addiction, Abuse, and Misuse Inform patients that the use of buprenorphine transdermal system, even when taken as recommended, can result in addiction, abuse, and misuse, which could lead to overdose and death [see Warnings and Precautions (5.1) ].
Instruct patients not to share buprenorphine transdermal system with others and to take steps to protect buprenorphine transdermal system from theft or misuse.
Life-Threatening Respiratory Depression Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting buprenorphine transdermal system or when the dosage is increased, and that it can occur even at recommended doses.
Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see Warnings and Precautions (5.2) , Overdosage (10) ].
Accidental Exposure Inform patients that accidental exposure, especially in children, may result in respiratory depression or death [see Warnings and Precautions (5.2) ] .
Interaction with Benzodiazepines Warn patients that it is extremely dangerous to self-administer benzodiazepines while taking buprenorphine transdermal system, and warn patients to use benzodiazepines concurrently with buprenorphine transdermal system only as directed by their physician [see Drug Interactions (7) ].
Interaction with Benzodiazepines and Other CNS Depressants Inform patients and caregivers that potentially fatal additive effects may occur if buprenorphine transdermal system is used with benzodiazepines or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids), and not to use these concomitantly unless supervised by a healthcare provider [see Warnings and Precautions (5.3) ] .
Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene).
Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose.
Discuss with the patient the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program) [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] .
Educate patients and caregivers on how to recognize the signs and symptoms of an overdose.
Explain to patients and caregivers that effects of opioid overdose reversal agents like naloxone and nalmefene are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if an opioid overdose reversal agent is administered [see Overdosage (10) ] .
Advise patients and caregivers:
how to treat with the overdose reversal agent in the event of an opioid overdose. to tell family and friends about the opioid overdose reversal agent and to keep it in a place where family and friends can access it in an emergency. to read the Patient Information (or other educational material) that will come with their opioid overdose reversal agent.
Emphasize the importance of doing this before an opioid emergency happens, so the patient and caregiver will know what to do.
Hyperalgesia and Allodynia Inform patients and caregivers not to increase opioid dosage without first consulting a clinician.
Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see Warnings and Precautions (5.9) , Adverse Reactions (6.2) ].
Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition called serotonin syndrome resulting from concomitant administration of serotonergic drugs.
Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away
if symptoms develop.
Instruct patients to inform their physicians if they are taking, or plan to take, serotonergic medications [see Drug Interactions (7) ] .
MAOI Interaction Inform patients to
avoid taking buprenorphine transdermal system while using any drugs that inhibit monoamine oxidase.
Patients should not start MAOIs while taking buprenorphine transdermal system [see Drug Interactions (7) ] .
Important Administration Instructions Instruct patients how to properly use buprenorphine transdermal system, including the following :
To carefully follow instructions for the application, removal, and disposal of buprenorphine transdermal system.
Each week, apply buprenorphine transdermal system to a different site based on the 8 described skin sites, with a minimum of 3 weeks between applications to a previously used site [see Dosage and Administration (2.7) ] .
To apply buprenorphine transdermal system to a hairless or nearly hairless skin site.
If none are available, instruct patients to clip the hair at the site and not to shave the area.
Instruct patients not to apply to irritated skin.
If the application site must be cleaned, use clear water only.
Soaps, alcohol, oils, lotions, or abrasive devices should not be used.
Allow the skin to dry before applying buprenorphine transdermal system [see Dosage and Administration (2.7) ] .
To avoid exposing the buprenorphine transdermal system application site to external heat sources, hot water, or prolonged direct sunlight [see Warnings and Precautions (5.6) ].
Important Discontinuation Instructions In order to
avoid developing withdrawal symptoms, instruct patients not to discontinue buprenorphine transdermal system without first discussing a tapering plan with the prescriber [see Dosage and Administration (2.5) ].
Driving or Operating Heavy Machinery Inform patients that buprenorphine transdermal system may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery.
Advise patients not to perform such tasks until they know how they will react to the medication [see Warnings and Precautions (5.20) ].
Constipation Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see Adverse Reactions (6) , Clinical Pharmacology (12.2) ] .
Adrenal Insufficiency Inform patients that buprenorphine transdermal system could cause adrenal insufficiency, a potentially life-threatening condition.
Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure.
Advise patients to seek medical attention if they experience a constellation of these symptoms [see Warnings and Precautions (5.11) ] .
Hypotension Inform patients that buprenorphine transdermal system may cause orthostatic hypotension and syncope.
Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [see Warnings and Precautions (5.12) ] .
Anaphylaxis Inform patients that anaphylaxis has been reported with ingredients contained in buprenorphine transdermal system.
Advise patients how to recognize such a reaction and when to seek medical attention [see Warnings and Precautions (5.18) , Contraindications (4) , Adverse Reactions (6) ].
Pregnancy Neonatal Opioid Withdrawal Syndrome Inform female patients of reproductive potential that the use of buprenorphine transdermal system for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [see Warnings and Precautions (5.4) , Use in Specific Populations (8.1) ].
Embryofetal Toxicity Inform female patients of reproductive potential that buprenorphine transdermal system can cause fetal harm and to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1) ] .
Lactation Advise patients that breastfeeding is not recommended during treatment with buprenorphine transdermal system [see Use in Specific Populations (8.2) ].
Infertility Inform patients that use of opioids for an extended period of time may cause reduced fertility.
It is not known whether these effects on fertility are reversible [see Use in Specific Populations (8.3) ].

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

FORMS AND STRENGTHS Buprenorphine transdermal system is a rectangular or square, beige-colored system consisting of a protective liner and functional layers.
Buprenorphine transdermal system is available in five strengths:
Buprenorphine transdermal system 5 mcg/hour (dimensions:
45 mm by 45 mm) Buprenorphine transdermal system 7.5 mcg/hour (dimensions:
58 mm by 45 mm) Buprenorphine transdermal system 10 mcg/hour (dimensions:
45 mm by 68 mm) Buprenorphine transdermal system 15 mcg/hour (dimensions:
59 mm by 72 mm) Buprenorphine transdermal system 20 mcg/hour (dimensions:
72 mm by 72 mm) Transdermal system:
5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour.
( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

Buprenorphine Transdermal System is supplied in cartons containing 4 individually packaged systems and a pouch containing 4 Patch-Disposal Units.
The systems are supplied in the strengths below:
5 mcg/hour:
square, beige-colored adhesive patches measuring 45 mm by 45 mm.
Each system is printed in blue with "Buprenorphine Transdermal System" and 5 mcg/hr.
NDC 42858-750-40 7.5 mcg/hour :
rectangular, beige-colored adhesive patches measuring 58 mm by 45 mm.
Each system is printed in blue with the "Buprenorphine Transdermal System" and 7.5 mcg/hr.
NDC 42858-353-40 10 mcg/hour:
rectangular, beige-colored adhesive patches measuring 68 mm by 45 mm.
Each system is printed in blue with the "Buprenorphine Transdermal System" and 10 mcg/hr.
NDC 42858-493-40 15 mcg/hour :
rectangular, beige-colored adhesive patches measuring 72 mm by 59 mm.
Each system is printed in blue with the "Buprenorphine Transdermal System" and 15 mcg/hr.
NDC 42858-586-40 20 mcg/hour :
square, beige-colored adhesive patches measuring 72 mm by 72 mm.
Each system is printed in blue with the "Buprenorphine Transdermal System" and 20 mcg/hr.
NDC 42858-839-40 Store buprenorphine transdermal system securely and dispose of properly [see Patient Counseling Information (17) ] .
Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

Quoted from the official label, section “How Supplied”.

How to store it

Store buprenorphine transdermal system securely and dispose of properly [see Patient Counseling Information (17) ] .
Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

Quoted from the official label, section “Storage and Handling”.

What is in it

Buprenorphine Transdermal System is a transdermal system providing systemic delivery of buprenorphine, a mu opioid partial agonist analgesic, continuously for 7 days.
The chemical name of buprenorphine is 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)- α-(1,1-dimethylethyl)-4, 5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy-α-methyl-, [5α, 7α, (S)].
The structural formula is:
The molecular weight of buprenorphine is 467.6; the empirical formula is C 29 H 41 NO 4 .
Buprenorphine occurs as a white or almost white powder and is very slightly soluble in water, freely soluble in acetone, soluble in methanol and ether, and slightly soluble in cyclohexane.
The pKa is 8.5 and the melting point is about 217°C.
System Components and Structure Five different strengths of buprenorphine transdermal system are available:
5, 7.5, 10, 15, and 20 mcg/hour (Table 6).
The proportion of buprenorphine mixed in the adhesive matrix is the same in each of the five strengths.
The amount of buprenorphine released from each system per hour is proportional to the active surface area of the system.
The skin is the limiting barrier to diffusion from the system into the bloodstream.
Table 6:
Buprenorphine Transdermal System Product Specifications Buprenorphine Delivery Rate (mcg/hour) Active Surface Area (cm 2 ) Total Buprenorphine Content (mg) Buprenorphine Transdermal System 5 6.25 5 Buprenorphine Transdermal System 7.5 9.375
7.5 Buprenorphine Transdermal System 10 12.5 10 Buprenorphine Transdermal System 15 18.75 15 Buprenorphine Transdermal System 20 25 20 Buprenorphine transdermal system is a rectangular or square, beige-colored system consisting of a protective liner and functional layers.
Proceeding from the outer surface toward the surface adhering to the skin, the layers are (1) a beige-colored web backing layer;
(2) an adhesive rim without buprenorphine;
(3) a separating layer over the buprenorphine-containing adhesive matrix;
(4) the buprenorphine- containing adhesive matrix; and (5) a peel-off release liner.
Before use, the release liner covering the adhesive layer is removed and discarded.
Figure 1: Cross-Section Diagram of Buprenorphine Transdermal System (not to scale).
The active ingredient in buprenorphine transdermal system is buprenorphine.
The inactive ingredients in each system are:
levulinic acid, oleyl oleate, povidone, and polyacrylate cross-linked with aluminum.
Chemical Structure Figure 1

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

This label’s list of inactive ingredients names none of: lactose, wheat or gluten, colour dyes, sugars, sugar alcohols, alcohol (ethanol), aspartame (phenylalanine), gelatin, peanut oil, soy, parabens, sulfites, titanium dioxide.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (7)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 7 of 7

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

Every strength and form (3)

CanadaNo exact match for this strength and form

Every strength and form (6)

Details

Made by	Rhodes Pharmaceuticals LLC
Active substance	Buprenorphine
Used in	Pain, sleep, mood, epilepsy and the brain
Strength	10 ug/h
Form	Patch
Route	Transdermal
Packs	4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 168 h in 1 PATCH
NDC	42858-493

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

48 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Tablet23 products
- 2 mg11
  2 mg · 11 companies
  +3 more
- 8 mg12
  8 mg · 12 companies
  +4 more
Patch, Extended Release20 products
- 5 ug/h4
  5 ug/h · 4 companies
- 7.5 ug/h4
  7.5 ug/h · 4 companies
- 10 ug/h4
  10 ug/h · 4 companies
- 15 ug/h4
  15 ug/h · 4 companies
- 20 ug/h4
  20 ug/h · 4 companies
Patch5 products
- 5 ug/h
- 7.5 ug/h
- 10 ug/h
- 15 ug/h
- 20 ug/h

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Brixadi8 mg/.16mLPrescription onlyInjection Braeburn Inc. · Buprenorphine Brixadi16 mg/.32mLPrescription onlyInjection Braeburn Inc. · Buprenorphine Brixadi24 mg/.48mLPrescription onlyInjection Braeburn Inc. · Buprenorphine Brixadi128 mg/.36mLPrescription onlyInjection Braeburn Inc. · Buprenorphine Brixadi32 mg/.64mLPrescription onlyInjection Braeburn Inc. · Buprenorphine Brixadi64 mg/.18mLPrescription onlyInjection Braeburn Inc. · Buprenorphine

See every product with Buprenorphine